Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
503
Total raised
£3.8B
disclosed amounts
This month
£36.9M
raised so far
The Leeds spinout secured backing led by Northern Gritstone to prepare its microfluidic device for human trials.
"At IVFmicro, we are harnessing years of research into reproductive biology to create a practical, accessible solution that can improve outcomes for patients undergoing fertility treatment. Our goal is to make IVF more effective, more predictable, and ultimately more hopeful for those striving to start a family."
The Kent biotechnology spinout raised the capital from backers including XGEN Venture and the British Business Bank to push its lead treatment into clinical evaluation.
"Refractory epilepsy is a devastating condition causing unpredictable and life-threatening seizures, and affecting millions of patients worldwide. Our novel gene therapy EPY201 delivered directly to the seizure focus has the potential to stop seizures with a single, minimally invasive administration. In doing so, it will change the way refractory epilepsy has been treated for decades. We are proud to have the support of such high calibre investors as we progress into clinical trials."
The seed round was co-led by Shilling and Plus Partners to accelerate commercial expansion across the UK and Spain.
"Dementia is never just one person’s disease. It affects entire families, and carers often carry an enormous invisible burden."
The investment from Brighton Park Capital and Nic Humphries accompanies a strategic partnership with Clearcare and a leadership transition.
"Our partnership with PCS reflects our confidence in the PCS vision. Together we will advance their transformation journey and accelerate technologies that will drive better outcomes for the future of care."
Anglia Capital Group backs Norwich-based Virilitas Labs with a £100k investment.
"The founders demonstrated a strong grasp of the clinical and commercial needs in this space. Their technology addresses an important issue that resonates strongly with our investors, who are committed to backing impactful innovation. We’re thrilled to welcome Virilitas Labs into the ACG portfolio and support their next stage of growth."
